Collectively, our finding provides new insights into the use of HtrA2 as a novel biomarker of RA and the design of next-generation therapeutic strategies for RA, as the production of other inflammatory mediators is reduced by modulating the amount of HtrA2. Here, HTRA2 is linked to rheumatoid arthritis.